A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin

Inclusion Criteria: * Healthy male subjects between the ages of 19 and 50 years * Subjects with body mass index (BMI) between 18.5 and 29.9 kg/m2 and weight more than 50 kg * Subjects who agree with performing contraception during the study * Subjects who provides written informed consent Exclusion Criteria: * Subjects who have a current or prior history of cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, skin, psychiatric, or neurological diseases that is clinically significant * Subjects who have clinically significant allergic history or allergy to metformin, nilotinib, or other components of drug * Subjects with history of galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption * Subjects with hypokalemia or hypomagnesemia at screening * Subjects with QTcF \> 450 or clinically significant findings on 12-lead ECG at screening * Subjects with fasting plasma glucose lower than 70 mg/dL or upper than 126 mg/dL at screening * Subjects who have history of gastrointestinal surgery * Subjects with creatinine clearance ≤ 60mL/min at screening * Subjects with AST or ALT ≥ 2-folds of upper normal limit * Subjects who reports less than 12 points on taste test at screening * Subjects who have administrated drugs that are known to cause significant drug-drug interaction with investigational drugs within 2 weeks prior to dosing * Whole blood donation within 60 days prior to dosing, or apheresis donation within 20 days prior to dosing, or received blood donation within 30 days prior to dosing * Subjects who participated in a previous clinical trial within 6 months prior to dosing * Subjects with a history of alcohol abuse * Subjects who are determined as unsuitable for clinical trial participation by investigator's decision